Using Bcr-Abl to examine mechanisms by which Abl kinase regulates morphogenesis in Drosophila

被引:23
|
作者
Stevens, Traci L. [1 ,3 ]
Rogers, Edward M. [1 ]
Koontz, Laura M. [1 ]
Fox, Donald T. [1 ]
Homem, Catarina C. F. [1 ]
Nowotarski, Stephanie H. [1 ]
Artabazon, Nicholas B. [3 ]
Peifer, Mark [1 ,2 ]
机构
[1] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Randolph Macon Coll, Dept Biol, Ashland, VA 23005 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E07-01-0008
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Signaling by the nonreceptor tyrosine kinase Abelson (Abl) plays key roles in normal development, whereas its inappropriate activation helps trigger the development of several forms of leukemia. Abl is best known for its roles in axon guidance, but Abl and its relatives also help regulate embryonic morphogenesis in epithelial tissues. Here, we explore the role of regulation of Abl kinase activity during development. We first compare the subcellular localization of Abl protein and of active Abl, by using a phosphospecific antibody, providing a catalog of places where Abl is activated. Next, we explore the consequences for morphogenesis of overexpressing wild-type Abl or expressing the activated form found in leukemia, Bcr-Abl. We find dose-dependent effects of elevating Abl activity on morphogenetic movements such as head involution and dorsal closure, on cell shape changes, on cell protrusive behavior, and on the organization of the actin cytoskeleton. Most of the effects of Abl activation parallel those caused by reduction in function of its target Enabled. Abl activation leads to changes in Enabled phosphorylation and localization, suggesting a mechanism of action. These data provide new insight into how regulated Abl activity helps direct normal development and into possible biological functions of Bcr-Abl.
引用
收藏
页码:378 / 393
页数:16
相关论文
共 50 条
  • [41] Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias
    Katsoulas, A
    Rachid, Z
    Brahimi, F
    McNamee, J
    Jean-Claude, BJ
    LEUKEMIA RESEARCH, 2005, 29 (06) : 693 - 700
  • [42] Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Mian, Afsar Ali
    Metodieva, Anna
    Badura, Susanne
    Khateb, Mamduh
    Ruimi, Nili
    Najajreh, Yousef
    Ottmann, Oliver Gerhard
    Mahajna, Jamal
    Ruthardt, Martin
    BMC CANCER, 2012, 12
  • [43] Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells
    Gaston, I
    Stenberg, PE
    Bhat, A
    Druker, BJ
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (01) : 77 - 86
  • [44] Mechanisms and implications of imatinib resistance mutations in BCR-ABL
    Nardi, V
    Azam, M
    Daley, GQ
    CURRENT OPINION IN HEMATOLOGY, 2004, 11 (01) : 35 - 43
  • [45] Out Foxing Bcr-Abl
    Claxton, David F.
    CANCER BIOLOGY & THERAPY, 2011, 11 (08) : 769 - 770
  • [46] Osteopontin is upregulated by BCR-ABL
    Flamant, S
    Kortulewski, T
    Dugray, A
    Bonnet, ML
    Guillier, M
    Guilhot, F
    Bourhis, JH
    Vainchenker, W
    Roux, DTL
    Turhan, AG
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (04) : 1378 - 1384
  • [47] Molecular Pathways: BCR-ABL
    Cilloni, Daniela
    Saglio, Giuseppe
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 930 - 937
  • [48] The chimeric BCR-ABL gene
    Groffen, J
    Heisterkamp, N
    BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (02): : 187 - 201
  • [49] BCR-ABL gene variants
    Melo, JV
    BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (02): : 203 - 222
  • [50] Allosteric inhibition of BCR-ABL
    Hassan, A. Quamrul
    Sharma, Sreenath V.
    Warmuth, Markus
    CELL CYCLE, 2010, 9 (18) : 3710 - 3714